European Medicines Agency
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Commonwealth Games ~ Nobel Prizes ~ Kim Jong-il ~ Hamid Karzai ~ Ed Miliband ~ Tony Abbott ~ Kathleen Sebelius ~ US Elections ~ Other International News
Home / International News / Press Releases / 2010 / October / October 12, 2010
European Medicines Agency approves TWYNSTA® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours
Cholesterol

European Medicines Agency approves TWYNSTA® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours

Spuds 'can be a part of weight loss programs'

Insulin resistance may be linked to stroke risk

More on Cholesterol

Diabetes

European Medicines Agency approves TWYNSTA® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours

Brit girl, 7, risks brain damage if she eats any protein

Blame your mom for your muffin top or thunder thighs

More on Diabetes

Blood Pressure

Living under a flight path 'ups heart attack risk by 30pc'

Yoga benefits childhood cancer patients and their parents

Clinical trials show effective weight loss strategies for obese

More on Blood Pressure

Heart attack

European Medicines Agency approves TWYNSTA® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours

More strokes, fewer heart attacks with carotid stents: Study

Insulin resistance may be linked to stroke risk

More on Heart attack

Top News

144 Section in Hyderabad ahead of Ayodhya verdict

18 killed, several injured as bus falls into river in Bulandshahr

Pak's flawed Afghan policy of support to terror groups will bite back hard: Editorial

Ajay Devgan prays for success of his film in Ajmer

Pranab Mukherjee seeks more financial sector reforms

Australia asks CWG organizers for better treatment at closing ceremony

Study to find whether leptin helps type 1 diabetic patients

New study confirms smoking, cancer link (reissue)

European Medicines Agency approves TWYNSTA® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours

Ingelheim, Germany

Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for the treatment of hypertension in adults whose blood pressure is not adequately controlled on amlodipine or as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets containing the same component doses.

Prof Michael Böhm (Photo: Business Wire)

Prof Michael Böhm (Photo: Business Wire)

TWYNSTA® is a new highly effective and well tolerated single pill combination therapy of telmisartan, an angiotensin receptor blocker and amlodipine, a calcium channel blocker, for the treatment of hypertension. It delivers BP reductions of up to 50 mmHg and controls BP for the full 24 hours in up to 83% of patients.1-4

TWYNSTA® consistently reduces blood pressure in a broad range of patients including those with mild, moderate and severe hypertension. In particular, it is effective in hypertensive patients with added risk such as those with obesity, metabolic syndrome and diabetes.

Both telmisartan and amlodipine have a proven evidence base in cardiovascular outcomes. TWYNSTA® combines telmisartan and amlodipine the two longest acting agents in each class. 1-4 Of the ARB class, only telmisartan is indicated to reduce CV morbidity (myocardial infarction [heart attack] and stroke) in a wide range of patients at risk of serious cardiac events.5,12

Professor Michael Böhm, Director and Chief of Department of Internal Medicine and Cardiology at the University of Saarland in Germany said, “For patients at higher risk of cardiovascular disease, that is patients with higher blood pressure, this combination will offer particular efficacy advantages over monotherapies, and possibly over other combination therapies. It is well tolerated and patients may experience less side effects when compared with amlodipine alone. Both factors are highly relevant to the treating physicians because they ensure patients are less likely to discontinue their treatment.”

The approval of TWYNSTA® by the European Commission follows a review of three pivotal clinical trials. Results from these studies show that TWYNSTA® 2-4,13-15:

In addition, results from a recent double-blind, randomised, controlled trial in patients with severe hypertension (TEAMSTA severe HTN) showed that:

Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim, commented: “We are delighted to receive European approval of TWYNSTA®. The data show it is effective and well tolerated in a range of hypertensive patients including those with additional risk factors such as diabetes and obesity and we believe that it will provide an important treatment option for both physicians and patients to achieve good blood pressure control.”

High blood pressure is the number one risk factor for CV disease and responsible for more deaths than any other single CV risk factor including high cholesterol, diabetes or smoking.4 A large meta-analysis of 61 studies including about 1 million patients (12.7 million patient years) suggests that a reduction of 2 mmHg in systolic blood pressure decreases the risk of CV events such as myocardial infarction and stroke by 7-10%.16

TWYNSTA® was approved in the US in October 2009. Boehringer Ingelheim is committed to make this valuable new therapeutic option available to patients and health care professionals as soon as possible.

To view ‘Notes to Editors’ and References, please click on the link below:

http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2010/12_october_2010_Twynsta.html

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6462713&lang=en

\


MULTIMEDIA AVAILABLE : http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6462713

Source:Business Wire (Business Wire India)

Link to this page


Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us